Stifel raised the price target for the MEDNAX Inc. (NYSE:MD) stock to “a Hold”. The rating was released on June 23, 2021. We previously noted in another research note published on October 19, 2020 by Deutsche Bank that downgraded the stock from a Hold to a Sell with a price target of $12 for MD stock. The research report from Citigroup has downgraded the stock from Buy to Neutral, with a price target set at $29. The stock was upgraded by Stifel, who disclosed in a research note on December 12, 2019, from Hold to Buy and set the price objective to $33.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
The latest trade, Performances and Moving Averages give us the following Picture
The share price of MEDNAX Inc. (NYSE:MD) raised 9.26% to close Friday’s market session at $33.14, higher as compared to yesterday’s close. The stock price fluctuated between $30.78 and $33.859 throughout the trading session with the volume trading being 956785 shares, which represented a significant variation when compared to the three months average volume of 615.60K shares. The firm’s stock price fluctuated 13.80% within the last five trades and 13.45% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 28.20% in the last 6 months and 3.24% was added to its value over the previous 3 months. MD stock is trading at a margin of 13.54%, 8.44% and 28.71% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, MD deals in the Healthcare domain. The stock is trading -3.07 percent below its 52-week high and 165.76 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 65.51. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does MEDNAX Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
The stock’s market cap achieved a total value of $2.90 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The price-to-earnings ratio for MEDNAX Inc. (NYSE:MD) is 193.80. The price-to-earnings ratio is a method of assessing corporate values by comparing them to their per-share profit. Forward P/E stands at 20.26. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 1.67 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 3.65, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
MEDEL ROGER MD, the Director at MEDNAX Inc. (MD) has sold 100,000 shares of firm on Apr 01 at a price of $25.40 against the total amount of $2.54 million. In another inside trade, MEDEL ROGER MD, Director of MEDNAX Inc. (NYSE:MD) sold 100,000 shares of the firm on Jan 04 for a total worth of $2.37 million at a price of $23.66. An inside trade which took place on Dec 10, Director of MEDNAX Inc. MEDEL ROGER MD sold 33,194 shares of firm against total price of $0.76 million at the cost of $23.04 per share.